Study On The Effect Of TACE On The Survival Of Patients With Microvascular Invasion After Radical Resection Of Hepatocellular Carcinoma

Objective:To investigate the associated risk factors on the patients of hepatocellular carcinoma with microvascular invasion and whether they could benefit from postoperative transcatheter arterial chemoembolization.Methods:Retrospective analysed the 54 clinical cases from the Second Affiliated Hospital Zhejiang University School Of Medicine between March 2011 and January 2016, those patients had gone through liver cancer radical surgery and postoperative pathologic diagnosis ensure HCC with MVI or not.Result:Study included 54 cases that meet the criteria; MVI negative group contains 25 cases, Non-TACE group has 15 cases, TACE group has 10 patients; MVI positive group has 29 patients, consist of 17 patients in Non-TACE group and 12 cases in TACE group.Up to January 2016,52 patients have complete follow-up and the follow-up rate is 96.30%(52/54, MVI positive and negative group each lost one case). The total average follow-up time is 22.17 ± 12.99 months, median follow-up time is 20.50 months; in MVI positive group, the average follow-up time is 23.07 ± 14.49 months and median follow-up time is 20.00 months; in MVI negative group, the average follow-up time is 21.12 ± 11.21 months and the median follow-up time is 21.00 months. Univariate analysis shows gender and the number of liver tumors have statistically significant (P <0.05), the further multivariate analysis indicates that the number of liver tumors is the independent risk factor that affect HCC accompany with MVI or not (P= 0.029).After analysis data on the tumor-free survival and overall survival of patients of HCC with MVI or not, whether underwent postoperative TACE treatment or not has no significantly different in improving tumor-free survival time and prolonging overall survival time.Conclusion:The number of liver tumors is the independent risk factor that affect HCC accompany with MVI or not; patients of HCC can not benefit from postoperative TACE; whether hepatocellular carcinoma with MVI can take benefit from postoperative TACE need randomized controlled clinical trials to explore.